Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EPS (Basic) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EPS (Basic) for 4 consecutive years, with -$0.27 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 73.0% to -$0.27 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.04 through Dec 2025, up 42.64% year-over-year, with the annual reading at -$3.03 for FY2025, 42.72% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.27 at Phathom Pharmaceuticals, up from -$0.41 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.27 in Q4 2025, with the low at -$1.56 in Q2 2024.
  • Average EPS (Basic) over 4 years is -$1.08, with a median of -$1.19 recorded in 2022.
  • The sharpest move saw EPS (Basic) tumbled 85.71% in 2024, then skyrocketed 73.0% in 2025.
  • Over 4 years, EPS (Basic) stood at -$1.33 in 2022, then fell by 9.02% to -$1.45 in 2023, then soared by 31.03% to -$1.0 in 2024, then surged by 73.0% to -$0.27 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.27, -$0.41, and -$1.05 for Q4 2025, Q3 2025, and Q2 2025 respectively.